Decitabine treatment of glioma-initiating cells enhances immune recognition and killing

Cristina Riccadonna, Céline Yacoub Maroun, Romain Vuillefroy De Silly, Margaux Boehler, Marta Calvo Tardón, Simone Jueliger, Pietro Taverna, Leticia Barba, Eliana Marinari, Serena Pellegatta, Esen Yonca Bassoy, Denis Martinvalet, Pierre Yves Dietrich, Paul R. Walker

Research output: Contribution to journalArticle

Abstract

Malignant gliomas are aggressive brain tumours with very poor prognosis. The majority of glioma cells are differentiated (glioma-differentiated cells: GDCs), whereas the smaller population (glioma-initiating cells, GICs) is undifferentiated and resistant to conventional therapies. Therefore, to better target this pool of heterogeneous cells, a combination of diverse therapeutic approaches is envisaged. Here we investigated whether the immunosensitising properties of the hypomethylating agent decitabine can be extended to GICs. Using the murine GL261 cell line, we demonstrate that decitabine augments the expression of the death receptor FAS both on GDCs and GICs. Interestingly, it had a higher impact on GICs and correlated with an enhanced sensitivity to FASL-mediated cell death. Moreover, the expression of other critical molecules involved in cognate recognition by cytotoxic T lymphocytes, MHCI and ICAM-1, was upregulated by decitabine treatment. Consequently, T-cell mediated killing of both GDCs and GICs was enhanced, as was T cell proliferation after reactivation. Overall, although GICs are described to resist classical therapies, our study shows that hypomethylating agents have the potential to enhance glioma cell recognition and subsequent destruction by immune cells, regardless of their differentiation status. These results support the development of combinatorial treatment modalities including epigenetic modulation together with immunotherapy in order to treat heterogenous malignancies such as glioblastoma.

Original languageEnglish
Article numbere0162105
JournalPLoS One
Volume11
Issue number8
DOIs
Publication statusPublished - Aug 1 2016

Fingerprint

decitabine
T-cells
Glioma
Cells
Death Domain Receptors
Cell proliferation
Cell death
cells
Intercellular Adhesion Molecule-1
Tumors
Brain
Therapeutics
Modulation
Molecules
therapeutics
T-lymphocytes
T-Lymphocytes

ASJC Scopus subject areas

  • Medicine(all)
  • Biochemistry, Genetics and Molecular Biology(all)
  • Agricultural and Biological Sciences(all)

Cite this

Riccadonna, C., Yacoub Maroun, C., Vuillefroy De Silly, R., Boehler, M., Calvo Tardón, M., Jueliger, S., ... Walker, P. R. (2016). Decitabine treatment of glioma-initiating cells enhances immune recognition and killing. PLoS One, 11(8), [e0162105]. https://doi.org/10.1371/journal.pone.0162105

Decitabine treatment of glioma-initiating cells enhances immune recognition and killing. / Riccadonna, Cristina; Yacoub Maroun, Céline; Vuillefroy De Silly, Romain; Boehler, Margaux; Calvo Tardón, Marta; Jueliger, Simone; Taverna, Pietro; Barba, Leticia; Marinari, Eliana; Pellegatta, Serena; Bassoy, Esen Yonca; Martinvalet, Denis; Dietrich, Pierre Yves; Walker, Paul R.

In: PLoS One, Vol. 11, No. 8, e0162105, 01.08.2016.

Research output: Contribution to journalArticle

Riccadonna, C, Yacoub Maroun, C, Vuillefroy De Silly, R, Boehler, M, Calvo Tardón, M, Jueliger, S, Taverna, P, Barba, L, Marinari, E, Pellegatta, S, Bassoy, EY, Martinvalet, D, Dietrich, PY & Walker, PR 2016, 'Decitabine treatment of glioma-initiating cells enhances immune recognition and killing', PLoS One, vol. 11, no. 8, e0162105. https://doi.org/10.1371/journal.pone.0162105
Riccadonna C, Yacoub Maroun C, Vuillefroy De Silly R, Boehler M, Calvo Tardón M, Jueliger S et al. Decitabine treatment of glioma-initiating cells enhances immune recognition and killing. PLoS One. 2016 Aug 1;11(8). e0162105. https://doi.org/10.1371/journal.pone.0162105
Riccadonna, Cristina ; Yacoub Maroun, Céline ; Vuillefroy De Silly, Romain ; Boehler, Margaux ; Calvo Tardón, Marta ; Jueliger, Simone ; Taverna, Pietro ; Barba, Leticia ; Marinari, Eliana ; Pellegatta, Serena ; Bassoy, Esen Yonca ; Martinvalet, Denis ; Dietrich, Pierre Yves ; Walker, Paul R. / Decitabine treatment of glioma-initiating cells enhances immune recognition and killing. In: PLoS One. 2016 ; Vol. 11, No. 8.
@article{41c7c45239a6441eb82dacab082be13e,
title = "Decitabine treatment of glioma-initiating cells enhances immune recognition and killing",
abstract = "Malignant gliomas are aggressive brain tumours with very poor prognosis. The majority of glioma cells are differentiated (glioma-differentiated cells: GDCs), whereas the smaller population (glioma-initiating cells, GICs) is undifferentiated and resistant to conventional therapies. Therefore, to better target this pool of heterogeneous cells, a combination of diverse therapeutic approaches is envisaged. Here we investigated whether the immunosensitising properties of the hypomethylating agent decitabine can be extended to GICs. Using the murine GL261 cell line, we demonstrate that decitabine augments the expression of the death receptor FAS both on GDCs and GICs. Interestingly, it had a higher impact on GICs and correlated with an enhanced sensitivity to FASL-mediated cell death. Moreover, the expression of other critical molecules involved in cognate recognition by cytotoxic T lymphocytes, MHCI and ICAM-1, was upregulated by decitabine treatment. Consequently, T-cell mediated killing of both GDCs and GICs was enhanced, as was T cell proliferation after reactivation. Overall, although GICs are described to resist classical therapies, our study shows that hypomethylating agents have the potential to enhance glioma cell recognition and subsequent destruction by immune cells, regardless of their differentiation status. These results support the development of combinatorial treatment modalities including epigenetic modulation together with immunotherapy in order to treat heterogenous malignancies such as glioblastoma.",
author = "Cristina Riccadonna and {Yacoub Maroun}, C{\'e}line and {Vuillefroy De Silly}, Romain and Margaux Boehler and {Calvo Tard{\'o}n}, Marta and Simone Jueliger and Pietro Taverna and Leticia Barba and Eliana Marinari and Serena Pellegatta and Bassoy, {Esen Yonca} and Denis Martinvalet and Dietrich, {Pierre Yves} and Walker, {Paul R.}",
year = "2016",
month = "8",
day = "1",
doi = "10.1371/journal.pone.0162105",
language = "English",
volume = "11",
journal = "PLoS One",
issn = "1932-6203",
publisher = "Public Library of Science",
number = "8",

}

TY - JOUR

T1 - Decitabine treatment of glioma-initiating cells enhances immune recognition and killing

AU - Riccadonna, Cristina

AU - Yacoub Maroun, Céline

AU - Vuillefroy De Silly, Romain

AU - Boehler, Margaux

AU - Calvo Tardón, Marta

AU - Jueliger, Simone

AU - Taverna, Pietro

AU - Barba, Leticia

AU - Marinari, Eliana

AU - Pellegatta, Serena

AU - Bassoy, Esen Yonca

AU - Martinvalet, Denis

AU - Dietrich, Pierre Yves

AU - Walker, Paul R.

PY - 2016/8/1

Y1 - 2016/8/1

N2 - Malignant gliomas are aggressive brain tumours with very poor prognosis. The majority of glioma cells are differentiated (glioma-differentiated cells: GDCs), whereas the smaller population (glioma-initiating cells, GICs) is undifferentiated and resistant to conventional therapies. Therefore, to better target this pool of heterogeneous cells, a combination of diverse therapeutic approaches is envisaged. Here we investigated whether the immunosensitising properties of the hypomethylating agent decitabine can be extended to GICs. Using the murine GL261 cell line, we demonstrate that decitabine augments the expression of the death receptor FAS both on GDCs and GICs. Interestingly, it had a higher impact on GICs and correlated with an enhanced sensitivity to FASL-mediated cell death. Moreover, the expression of other critical molecules involved in cognate recognition by cytotoxic T lymphocytes, MHCI and ICAM-1, was upregulated by decitabine treatment. Consequently, T-cell mediated killing of both GDCs and GICs was enhanced, as was T cell proliferation after reactivation. Overall, although GICs are described to resist classical therapies, our study shows that hypomethylating agents have the potential to enhance glioma cell recognition and subsequent destruction by immune cells, regardless of their differentiation status. These results support the development of combinatorial treatment modalities including epigenetic modulation together with immunotherapy in order to treat heterogenous malignancies such as glioblastoma.

AB - Malignant gliomas are aggressive brain tumours with very poor prognosis. The majority of glioma cells are differentiated (glioma-differentiated cells: GDCs), whereas the smaller population (glioma-initiating cells, GICs) is undifferentiated and resistant to conventional therapies. Therefore, to better target this pool of heterogeneous cells, a combination of diverse therapeutic approaches is envisaged. Here we investigated whether the immunosensitising properties of the hypomethylating agent decitabine can be extended to GICs. Using the murine GL261 cell line, we demonstrate that decitabine augments the expression of the death receptor FAS both on GDCs and GICs. Interestingly, it had a higher impact on GICs and correlated with an enhanced sensitivity to FASL-mediated cell death. Moreover, the expression of other critical molecules involved in cognate recognition by cytotoxic T lymphocytes, MHCI and ICAM-1, was upregulated by decitabine treatment. Consequently, T-cell mediated killing of both GDCs and GICs was enhanced, as was T cell proliferation after reactivation. Overall, although GICs are described to resist classical therapies, our study shows that hypomethylating agents have the potential to enhance glioma cell recognition and subsequent destruction by immune cells, regardless of their differentiation status. These results support the development of combinatorial treatment modalities including epigenetic modulation together with immunotherapy in order to treat heterogenous malignancies such as glioblastoma.

UR - http://www.scopus.com/inward/record.url?scp=84990241948&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84990241948&partnerID=8YFLogxK

U2 - 10.1371/journal.pone.0162105

DO - 10.1371/journal.pone.0162105

M3 - Article

AN - SCOPUS:84990241948

VL - 11

JO - PLoS One

JF - PLoS One

SN - 1932-6203

IS - 8

M1 - e0162105

ER -